ReviewArthritis research & therapy2009
Gene therapy of the rheumatic diseases: 1998 to 2008.
Review in Arthritis research & therapy, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Intra-articular delivery of AAV vectors encoding PD-L1 attenuates joint inflammation and tissue damage in a mouse model of rheumatoid arthritis.Frontiers in immunology · 2023Article
- PUMA gene delivery to synoviocytes reduces inflammation and degeneration of arthritic joints.Nature communications · 2017Article
- How the microbiota shapes rheumatic diseases.Nature reviews. Rheumatology · 2016Review
- Arthritis gene therapy and its tortuous path into the clinic.Translational research : the journal of laboratory and clinical medicine · 2013Review
- Concise review: the clinical application of mesenchymal stem cells for musculoskeletal regeneration: current status and perspectives.Stem cells translational medicine · 2012Review
- Immunosuppressive exosomes: a new approach for treating arthritis.International journal of rheumatology · 2012Article
- Investigation of the peak action wavelength of light-activated gene transduction.Gene therapy · 2011Article
- Arthritis gene therapy trials reach phase II.The Journal of rheumatology · 2010Article
- Therapeutic strategies for SLE involving cytokines: mechanism-oriented therapies especially IFN-gamma targeting gene therapy.Journal of biomedicine & biotechnology · 2010Review
- Modulation of collagen-induced arthritis by adenovirus-mediated intra-articular expression of modified collagen type II.Arthritis research & therapy · 2010Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
During the decade since the launch of Arthritis Research, the application of gene therapy to the rheumatic diseases has experienced the same vicissitudes as the field of gene therapy as a whole. There have been conceptual and technological advances and an increase in the number of clinical trials. However, funding has been unreliable and a small number of high-profile deaths in human trials, including one in an arthritis gene therapy trial, have provided ammunition to skeptics. Nevertheless, steady progress has been made in a number of applications, including rheumatoid arthritis and osteoarthritis, Sjögren syndrome, and lupus. Clinical trials in rheumatoid arthritis have progressed to phase II and have provided the first glimpses of possible efficacy. Two phase I protocols for osteoarthritis are under way. Proof of principle has been demonstrated in animal models of Sjögren syndrome and lupus. For certain indications, the major technological barriers to the development of genetic therapies seem to have been largely overcome. The translational research necessary to turn these advances into effective genetic medicines requires sustained funding and continuity of effort.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.